Bonesupport Holding

Share Issue/Capital Change • Dec 30, 2022

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes. As per December 30, 2022, the total number of shares in BONESUPPORT HOLDING AB (publ) amounts to 66,174,635, divided into 64,532,197 ordinary shares with one vote per share and 1,642,438 series C shares with one-tenth of a vote per share, corresponding to a total of 64,696,440.8 votes.

The change in number of shares and votes is partly due to a directed issue and repurchase of series C shares to secure delivery of performance shares for the share saving program LTI 2021 and partly due to the exercise of warrants within the employee stock options program 2012/2022.

The directed issue increased the number of series C shares by 639,572 shares, corresponding to 63,957.2 votes. The exercise of warrants increased the number of ordinary shares by 11,000 shares, corresponding to the same number of votes.

In total, during December 2022 the number of shares has increased by 650,572 shares, of which 11,000 are ordinary shares and 639,572 are series C shares, and the number of votes has increased by 74,957.2 votes.

For more information contact:

BONESUPPORT Holding AB Emil Billbäck, CEO +46 (0) 46 286 53 70

Håkan Johansson, CFO +46 (0) 46 286 53 70 ir@bonesupport.com

Cord Communications Charlotte Stjerngren +46 (0) 708 76 87 87 charlotte.stjerngren@cordcom.se www.cordcom.se

This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2022-12-30 08:45 CET.

Press Release 30 December 2022 08:45:00 CET

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport. com for more information.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)